Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|11|1737-1746

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.11, 2015-06, pp. : 1737-1746

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Relationship between Treatment Effects on Progression-Free Survival and Overall Survival in Multiple Myeloma: A Systematic Review and Meta-Analysis of Published Clinical Trial Data

By  

Oncology Research and Treatment, Vol. 38, Iss. 3, 2015-02 ,pp. : 88-94

Karger

Access to resources Recommend Favorite

Relationship between 6‐ and 9‐month progression‐free survival and overall survival in patients with metastatic urothelial cancer treated with first‐line cisplatin‐based chemotherapy

By  

CANCER, Vol. 119, Iss. 16, 2013-08 ,pp. : 3020-3026

John Wiley & Sons Inc

Access to resources Recommend Favorite

Progression-Free Survival in Ovarian Cancer Is Reflected in Epigenetic DNA Methylation Profiles

By  

Oncology, Vol. 80, Iss. 1-2, 2011-05 ,pp. : 12-20

Karger

Access to resources Recommend Favorite

Relationship between progression‐free survival and overall survival in patients with advanced non‐small cell lung cancer treated with anticancer agents after first‐line treatment failure

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 2, 2015-06 ,pp. : 121-128

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bevacizumab Improves the Overall and Progression-Free Survival of Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracil-Based Regimens Irrespective of Baseline Risk

By  

Oncology, Vol. 75, Iss. 3-4, 2008-10 ,pp. : 215-223

Karger

Access to resources Recommend Favorite